Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.62 |
| ▸ | CA1 | P00915 | 3/20 | 0.62 |
| ▸ | CA2 | P00918 | 3/20 | 0.62 |
| ▸ | CA7 | P43166 | 3/20 | 0.62 |
| ▸ | CA9 | Q16790 | 3/20 | 0.62 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.62 |
| ▸ | ESR1 | P03372 | 1/20 | 0.52 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | CASP3 | P42574 | 1/20 | 0.51 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.51 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24527151 | 0.90 | CA12 (0.56) | CA12CA1CA2CA7CA9 | |
| SCHEMBL15276211 | 0.89 | CA12 (0.55) | CA12CA1CA2CA7CA9 | |
| SCHEMBL670880 | 0.89 | CA12 (0.55) | CA12CA1CA2CA7CA9 | |
| SCHEMBL24526854 | 0.89 | CA12 (0.55) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1401503 | 0.89 | CYP2C19 (0.60) | CA12CA1CA2CA7CA9 | |
| SCHEMBL26708988 | 0.89 | KDM4E (0.58) | CA12CA1CA2CA7CA9 | |
| SCHEMBL670577 | 0.87 | CA1 (0.53) | CA12CA1CA2CA7CA9 | |
| SCHEMBL977094 | 0.87 | NPC1 (0.59) | CA12CA1CA2CA7CA9 | |
| SCHEMBL4162787 | 0.87 | CA1 (0.53) | CA12CA1CA2CA7CA9 | |
| SCHEMBL28402874 | 0.86 | BRD4 (0.52) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118791394-A | Synthesis method of alpha-amino acid ester compound | 南通大学 | 2024-10-18 | — | — | CN | disclosed |
| US-20230121721-A1 | MONOACYLGLYCEROL LIPASE INHIBITORS | STICHTING HET NEDERLANDS KANKER INST ANTONI VAN LEEUWENHOEK ZIEKENHUIS (NL) | 2023-04-20 | — | — | US | disclosed |
| EP-4114829-A1 | MONOACYLGLYCEROL LIPASE INHIBITORS | Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis (NL) | 2023-01-11 | — | — | EP | disclosed |
| WO-2022129047-A2 | NOVEL MODULATORS OF THE NMDA RECEPTOR | H. LUNDBECK A/S (DK) | 2022-06-23 | — | — | WO | disclosed |
| WO-2022129047-A2 | NOVEL MODULATORS OF THE NMDA RECEPTOR | H. LUNDBECK A/S (DK) | 2022-06-23 | — | — | WO | disclosed |
| EP-3875452-A1 | MONOACYLGLYCEROL LIPASE INHIBITORS | Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis (NL) | 2021-09-08 | — | — | EP | disclosed |
| EP-2704720-B1 | PYRUVATE KINASE R ACTIVATORS FOR USE IN THERAPY | AGIOS PHARMACEUTICALS INC (US) | 2019-08-07 | — | — | EP | disclosed |
| US-10307422-B2 | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome | USHER III INITIATIVE, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| EP-2658543-B1 | PYRUVATE KINASE M2 (PKM2) ACTIVATORS FOR USE IN THERAPY | AGIOS PHARMACEUTICALS INC (US) | 2019-02-20 | — | — | EP | disclosed |
| US-20180207159-A1 | PYRAZOLOPYRIDAZINES AND METHODS FOR TREATING RETINAL-DEGENERATIVE DISEASES AND HEARING LOSS ASSOCIATED WITH USHER SYNDROME | BIOFOCUS DPI LTD. (GB) | 2018-07-26 | — | — | US | disclosed |
| EP-1863771-A2 | BENZAZOLE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE AS B-SECRETASE INHIBITORS | Transtech Pharma, Inc. (US) | 2007-12-12 | — | — | EP | disclosed |
| US-20070208015-A1 | 5-Morpholinylmethylthiophenyl Pharmaceutical Compounds As P38 MAP Kinase Modulators | ASTEX THERAPEUTICS, LTD. (UK) | 2007-09-06 | — | — | US | disclosed |
| US-20070082898-A1 | 5 Amino-2-carbonylthiophene derivatives for use as p38 map kinase inhibitors in the treatment of inflammatory diseases | ASTEX THERAPEUTICS LIMITED (GB) | 2007-04-12 | — | — | US | disclosed |
| EP-1756082-A1 | 5-MORPHOLINYLMETHYLTHIOPHENYL PHARMACEUTIAL COMPOUNDS AS P38 MAP KINASE MODULATORS | Astex Therapeutics Limited (GB) | 2007-02-28 | — | — | EP | disclosed |
| US-20060223849-A1 | Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors | HIGH POINT PHARMACEUTICALS, LLC | 2006-10-05 | — | — | US | disclosed |
| WO-2006099379-A2 | BENZAZOLE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE AS B-SECRETASE INHIBITORS | TRANSTECH PHARMA, INC. (US) | 2006-09-21 | — | — | WO | disclosed |
| WO-2006040569-A1 | THIOPHENE AMIDE COMPOUNDS FOR USE IN THE TREATMENT OR PROPHYLAXIS OF CANCERS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-04-20 | — | — | WO | disclosed |
| EP-1615907-A1 | 5-AMINO-2-CARBONYLTHIOPHENE DERIVATIVES FOR USE AS P38 MAP KINASE INHIBITORS IN THE TREATMENT OF INFLAMMATORY DISEASES | Astex Therapeutics Limited (GB) | 2006-01-18 | — | — | EP | disclosed |
| WO-2005100338-A1 | 5-MORPHOLINYLMETHYLTHIOPHENYL PHARMACEUTIAL COMPOUNDS AS P38 MAP KINASE MODULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2005-10-27 | — | — | WO | disclosed |
| WO-2004089929-A1 | 5-AMINO-2-CARBONYLTHIOPHENE DERIVATIVES FOR USE AS P38 MAP KINASE INHIBITORS IN THE TREATMENT OF INFLAMMATORY DISEASES | ASTEX THERAPEUTICS LIMITED (GB) | 2004-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230121721-A1 | MONOACYLGLYCEROL LIPASE INHIBITORS | MGLL, PNLIP, LIPA | CA12 3793/4885CA1 3413/4885CA2 2182/4885 |
| US-20070082898-A1 | 5 Amino-2-carbonylthiophene derivatives for use as p38 map kinase inhibitors in the treatment of inflammatory diseases | CNKSR1, NOX5, NOX1 | CA12 2982/4885CA1 1439/4885CA2 773/4885 |
| US-20070208015-A1 | 5-Morpholinylmethylthiophenyl Pharmaceutical Compounds As P38 MAP Kinase Modulators | MAPK1, MAPK3, MAPK10 | CA12 4821/4885CA1 4347/4885CA2 1882/4885 |
| US-20180207159-A1 | PYRAZOLOPYRIDAZINES AND METHODS FOR TREATING RETINAL-DEGENERATIVE DISEASES AND HEARING LOSS ASSOCIATED WITH USHER SYNDROME | ALDH1A2, ALDH1A3, NR2E3 | CA12 4570/4885CA1 4544/4885CA2 4133/4885 |
| US-10307422-B2 | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome | ALDH1A2, ALDH1A3, NR2E3 | CA12 4570/4885CA1 4544/4885CA2 4133/4885 |
| US-20060223849-A1 | Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors | BACE1, BACE2, APP | CA12 3221/4885CA1 631/4885CA2 1456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.